Recent

% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

  • TTPTTP TTPTTP May 22, 1998 8:05 AM Flag

    NEUROCRINE A GREAT BUY NOW

    I am a biotech analyst for my own firm. I think
    Neurocrine is a
    great overall company. The stock should
    do quite well towards the second half of 1998 and in
    1999. My price target is $18.
    This company has great
    management, science and a fantastic cash spending plan. This
    is a premier core biotech stock for any
    one
    interested in the industry. There are only a handfull of
    potential blockbuster biotechs, NBIX, LGND, SUGN, AXPH and
    CBMI.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Don't get me wrong that I wouldn't like to see 18$ but how would you justify that price. I don't even know how well there clinical trials are going. If you care to comment, that would be great.

      • 1 Reply to blythfund
      • NBIX has received Buy recommendations from
        Gruntal & Co., Prudential, Alex Brown Inc., Robert
        Stephens and Nationsbanc Montgomery with 12 month price
        projections from $16 to $22. Gruntal actually increased their
        projection from $15 to $18 from 2/98 to 5/13/98.
        The
        price targets are based upon current prices of
        comparable biotechs, i.e. GILD, Glfd, HGSI and NRGN, as well
        as a good deal of clinical data will be released in
        1998.
        I attended the Annual meeting 5-27-98. Overall I
        would say it was very informative and the following
        items were highlighted by Gary Lyons:
        1. Gary was
        very excited with the potential of the IL-4 Fusion
        Toxin being tested on brain cancer with the possibility
        of use for other types of cancer as well. (see news
        release of May 12, 1998). They expect to complete safety
        and efficacy trials by the end of 98 and if PH. III
        trials progress satisfactorily, submission to the FDA
        with expedited review status could occur by
        2000.
        2. The APL drug in Phase II could be far superior to
        the current MS drugs (Avonex, Betaseron) on the
        market.
        3. NBIX plans on entering into another research
        collaboration with a major parmaceutical co. before the end of
        the year.
        Hope this info. helps.
        Good Luck!

 
NBIX
49.58-0.19(-0.38%)12:01 PMEDT